This system achieves concomitant suppression of immunosuppressive checkpoints and stress-adaptive signaling through co-delivery of: CRISPR/Cas9 for PD-L1 ablation, and MnO2 nanoparticles for hypoxia alleviation, thereby potentiating therapeutic efficacy against advanced melanoma (37). The gene discussed is CD274; the disease is melanoma.